期刊
CLINICS IN LIVER DISEASE
卷 22, 期 1, 页码 189-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2017.08.013
关键词
NAFLD; NASH; Obeticholic acid; Elafibranor; Liraglutide; Cenicriviroc; Selonsertib
资金
- NIH
- Cirius (Octeta) Therapeutics
- Galmed
- Zydus
- Intercept
- Lilly
- Gilead
- Galectin Therapeutics
- Cumberland
This article discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据